Talk with the Experts: Clinical Case Studies and Treatment Decisions in Acute Myeloid Leukemia and Myelofibrosis - European Medical Journal

Talk with the Experts: Clinical Case Studies and Treatment Decisions in Acute Myeloid Leukemia and Myelofibrosis

Hematology

This symposium was sponsored by Celgene, a Bristol Myers Squibb company.


Catch up on this expert-led Satellite Symposium, titled ‘Talk with the Experts: Clinical Case Studies and Treatment Decisions in Acute Myeloid Leukemia (AML) and Myelofibrosis (MF)’, which was held at the EHA2024 Hybrid Congress.

Co-chairs Andrew Wei and John Mascarenhas, alongside speakers Gail Roboz and Martin Griesshammer, delivered informative presentations and participated in an interactive roundtable discussion.

During the roundtable, the expert faculty discussed latest advances, current clinical challenges, and the treatment landscape in AML and MF. In addition, they examined the importance of maintaining remission in AML and managing new options for MF, as well as the role of maintenance therapy in AML, along with the evolving treatment landscape in MF.

Sections:

  • Welcome and Introductions – 00:00-02:00
  • Expert Roundtable: Challenges in the Management of Patients with Acute Myeloid Leukemia and Myelofibrosis – 02:00-15:11
  • How I Treat My Patients: Maintaining Remission in Acute Myeloid Leukemia (Gail Roboz) – 15:11-31:40
  • How I Treat My Patients: Managing New Options for Myelofibrosis (Martin Griesshammer) – 31:40-48:33
  • Q&A | Discussion and Closing Remarks – 48:33-01:01:16

Faculty:

Co-chairs:

Andrew Wei
Peter MacCallum Cancer Centre, Melbourne, Australia

John Mascarenhas
Icahn School of Medicine, Mount Sinai Hospital, New York, USA

Speakers:

Gail Roboz
Weill Cornell Medicine, New York, USA

Martin Griesshammer
Johannes Wesling Medical Center, Minden, Germany

Job code: HE-GL-2400088
Date of preparation: June 2024

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?